You are here
Morpholino Publication Database
This database contains citations and abstracts for research using Morpholino oligos, as well as some review articles incorporating Morpholino data. You can search the content using the filter boxes below.
There are 259 scientific papers returned from the database with the search filters currently being used below.
There are 259 scientific papers returned from the database with the search filters currently being used below.
DG9-conjugated morpholino rescues phenotype in SMA mice by reaching the CNS via a subcutaneous administration
Citation:
JCI Insight. 2023;8(5):e160516. doi: 10.1172/jci.insight.160516. Online ahead of print Epub:
Not Epub Abstract:
Antisense oligonucleotide (AO)-mediated therapy is a promising strategy to treat several neurological diseases including spinal... Delivery Method:
peptide-linked Organism or Cell Type:
mice Citation Extract: Aslesh T, Erkut E, Ren J, Lim KRQ, Woo S, Hatlevig S, Moulton HM, Gosgnach S, Greer J, Maruyama R, Yokota T. DG9-conjugated morpholino rescues phenotype in SMA mice by reaching the CNS via a subcutaneous administration. JCI Insight. 2023;8(5):e160516. doi: 10.1172/jci.insight.160516. Online ahead of print. |
PPMOs: A Case Study for Cell-Penetrating Peptide Application
Citation:
In Cell-Penetrating Peptides (eds M. Oba and Y. Demizu). 2023:ch 15. doi:10.1002/9783527835997.ch15 Epub:
Not Epub Abstract:
The current state of the art for in vivo antisense morpholino technology is peptide-conjugated phosphorodiamidate morpholino... Delivery Method:
peptide-linked Citation Extract: Bittner S, Moulton ZX, Moulton HM. PPMOs: A Case Study for Cell-Penetrating Peptide Application. In Cell-Penetrating Peptides (eds M. Oba and Y. Demizu). 2023:ch 15. doi:10.1002/9783527835997.ch15. |
Peptide-Conjugated PMOs for the Treatment of Myotonic Dystrophy
Citation:
Methods Mol Biol. 2023;2587:209-237. doi: 10.1007/978-1-0716-2772-3_13 Epub:
Not Epub Abstract:
Antisense oligonucleotides (ASOs) have shown great therapeutic potential in the treatment of many neuromuscular diseases... Delivery Method:
peptide-linked Organism or Cell Type:
mice Citation Extract: Stoodley J, Miraz DS, Jad Y, Fischer M, Wood MJA, Varela MA. Peptide-Conjugated PMOs for the Treatment of Myotonic Dystrophy. Methods Mol Biol. 2023;2587:209-237. doi: 10.1007/978-1-0716-2772-3_13. |
Systemic PPMO-mediated dystrophin expression in the Dup2 mouse model of Duchenne muscular dystrophy
Citation:
Mol Ther Nucleic Acids. 2022 Nov 9;30:479-492. doi: 10.1016/j.omtn.2022.10.025. eCollection 2022 Dec 13. Epub:
Not Epub Abstract:
Duchenne muscular dystrophy (DMD) is a devastating muscle-wasting disease that arises due to the loss of dystrophin expression... Delivery Method:
peptide-linked Organism or Cell Type:
mice Citation Extract: Gushchina LV, Vetter TA, Frair EC, Bradley AJ, Grounds KM, Lay JW, Huang N, Suhaiba A, Schnell FJ, Hanson G, Simmons TR, Wein N, Flanigan KM. Systemic PPMO-mediated dystrophin expression in the Dup2 mouse model of Duchenne muscular dystrophy. Mol Ther Nucleic Acids. 2022 Nov 9;30:479-492. doi: 10.1016/j.omtn.2022.10.025. eCollection 2022 Dec 13.. |
P.120 Unlocking the potential of oligonucleotide therapeutics for Duchenne muscular dystrophy through enhanced delivery
Citation:
Neuromuscul Disord. 2022;32(Suppl 1):S99. doi:10.1016/j.nmd.2022.07.236 Epub:
Not Epub Abstract:
PGN-EDO51 is PepGen's clinical candidate to treat individuals with Duchenne muscular dystrophy (DMD) amenable to exon 51... Delivery Method:
peptide-linked Organism or Cell Type:
mice, non-human primates Citation Extract: Mellion M, McArthur J, Holland A, Gunnoo S, Ching S, Johnson R, Irwin C, Lonkar P, Bracegirdle S, Svenstrup N, Goyal J, Godfrey C, Larkindale J. P.120 Unlocking the potential of oligonucleotide therapeutics for Duchenne muscular dystrophy through enhanced delivery. Neuromuscul Disord. 2022;32(Suppl 1):S99. doi:10.1016/j.nmd.2022.07.236. |
O.14 EEV-Conjugated PMO results in nuclear foci reduction and aberrant splicing correction in myotonic dystrophy cell and animal models
Citation:
Neuromuscul Disord. 2022;32(Suppl 1):S96. doi:/10.1016/j.nmd.2022.07.224 Epub:
Not Epub Abstract:
Myotonic dystrophy type 1 (DM1) is the most common adult-onset muscular dystrophy, manifesting in multisystemic effects... Delivery Method:
peptide-linked Organism or Cell Type:
cell culture: patient-derived muytoubes, mice Citation Extract: Grigenrath M, Estrella N, Hicks A, Shen X, Wysk M, Kheirabadi M, Streeter M, Lian W, Liu N, Blake S, Brennan C, Li N, Batagui V, Oye K, Gao N, Wang D, Qian X, Sethuraman N. O.14 EEV-Conjugated PMO results in nuclear foci reduction and aberrant splicing correction in myotonic dystrophy cell and animal models. Neuromuscul Disord. 2022;32(Suppl 1):S96. doi:/10.1016/j.nmd.2022.07.224. |
Common and species-specific molecular signatures, networks, and regulators of influenza virus infection in mice, ferrets, and humans
Citation:
Sci Adv. 2022 Oct 7;8(40):eabm5859. doi: 10.1126/sciadv.abm5859. Epub 2022 Oct 5 Epub:
Not Epub Abstract:
Molecular responses to influenza A virus (IAV) infections vary between mammalian species. To identify conserved and species-... Delivery Method:
peptide-linked Organism or Cell Type:
mice Citation Extract: Forst CV, Martin-Sancho L, Tripathi S, Wang G, Dos Anjos Borges LG, Wang M, Geber A, Lashua L, Ding T, Zhou X, Carter CE, Metreveli G, Rodriguez-Frandsen A, Urbanowski MD, White KM, Stein DA, Moulton H, Chanda SK, Pache L, Shaw ML, Ross TM, Ghedin E, García-Sastre A, Zhang B. Common and species-specific molecular signatures, networks, and regulators of influenza virus infection in mice, ferrets, and humans. Sci Adv. 2022 Oct 7;8(40):eabm5859. doi: 10.1126/sciadv.abm5859. Epub 2022 Oct 5. |
Exon skipping induces uniform dystrophin rescue with dose-dependent restoration of serum miRNA biomarkers and muscle biophysical properties
Citation:
Mol Ther Nucleic Acids. 2022 Aug 25;29:955-968. doi: 10.1016/j.omtn.2022.08.033. eCollection 2022 Epub:
Not Epub Abstract:
Therapies that restore dystrophin expression are presumed to correct Duchenne muscular dystrophy (DMD), with antisense-mediated... Delivery Method:
peptide-linked Organism or Cell Type:
mice Citation Extract: Chwalenia K, Oieni J, Zemła J, Lekka M, Ahlskog N, Coenen-Stass AML, McClorey G, Wood MJA, Lomonosova Y, Roberts TC. Exon skipping induces uniform dystrophin rescue with dose-dependent restoration of serum miRNA biomarkers and muscle biophysical properties. Mol Ther Nucleic Acids. 2022 Aug 25;29:955-968. doi: 10.1016/j.omtn.2022.08.033. eCollection 2022. |
Helix-Stabilized Cell-Penetrating Peptides for Delivery of Antisense Morpholino Oligomers: Relationships among Helicity, Cellular Uptake, and Antisense Activity
Citation:
Bioconjug Chem. 2022 Jun 23. doi: 10.1021/acs.bioconjchem.2c00199. Online ahead of print Epub:
Yes Abstract:
The secondary structures of cell-penetrating peptides (CPPs) influence their properties including their cell-membrane... Delivery Method:
peptide-linked Organism or Cell Type:
cell culture: HeLa 705 Citation Extract: Takada H, Tsuchiya K, Demizu Y. Helix-Stabilized Cell-Penetrating Peptides for Delivery of Antisense Morpholino Oligomers: Relationships among Helicity, Cellular Uptake, and Antisense Activity. Bioconjug Chem. 2022 Jun 23. doi: 10.1021/acs.bioconjchem.2c00199. Online ahead of print. |
Anti-cancer effect of hUC-MSC-derived exosome-mediated delivery of PMO-miR-146b-5p in colorectal cancer
Citation:
Research Square 2022:[preprint] doi:10.21203/rs.3.rs-1704679/v1 Epub:
Not Epub Abstract:
Background: Antisense oligonucleotide (ASO) is a novel therapeutic platform for targeted cancer therapy. Colorectal cancer (CRC... Delivery Method:
peptide-linked exosomal Organism or Cell Type:
cell culture: CRC Citation Extract: Yu S, Liao R, Bai L, Guo M, Zhang Y, Zhang Y, Yang Q, Song Y, Li Z, Meng Q, Wang S, Huang X. Anti-cancer effect of hUC-MSC-derived exosome-mediated delivery of PMO-miR-146b-5p in colorectal cancer. Research Square 2022:[preprint] doi:10.21203/rs.3.rs-1704679/v1. |